Inventiva Aktie

5,45 EUR -0,06 EUR -1,09 %

07:05:01

STU

5,56 EUR -0,12 EUR -2,11 %

11.03.2026

PAR

Inventiva jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.1,18 Mrd. EUR

Div. Rendite0,00%

WKNA2DLV9

ISINFR0013233012

SymbolIVEVF

Inventiva Aktien News

Sortieren:Datum Meistgelesen

10.06.25GlobeNewswireInventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

27.05.25GlobeNewswireInventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

23.05.25GlobeNewswireInventiva reports 2025 First Quarter Financial Information¹

WerbungInventiva-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

23.05.25GlobeNewswireResults of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

22.05.25GlobeNewswireDescription of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

05.05.25GlobeNewswireInventiva secures the €116 million second tranche of its structured financing of up to €348 million

30.04.25GlobeNewswireCombined General Meeting of May 22, 2025 - Availability of the preparatory documents

30.04.25GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of April 11, 2025

24.04.25GlobeNewswireInventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanif

15.04.25GlobeNewswireInventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

01.04.25GlobeNewswireInventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

26.03.25GlobeNewswireInventiva reports its 2024 full year results and provides a business update

19.03.25GlobeNewswireInventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

26.02.25GlobeNewswireInventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

20.02.25GlobeNewswireInventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

10.02.25GlobeNewswireInventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

29.01.25GlobeNewswireInventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

24.01.25GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

22.01.25GlobeNewswireResults of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

17.12.24GlobeNewswireInventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

16.12.24GlobeNewswireInventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

12.12.24GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

21.11.24GlobeNewswireInventiva reports 2024 Third Quarter Financial Information¹

20.11.24GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of November 4, 2024

20.11.24GlobeNewswireCombined General Meeting of December 11, 2024 - Availability of the preparatory documents

15.11.24GlobeNewswireInventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® lat

30.10.24GlobeNewswireInventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

21.10.24GlobeNewswireInventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

14.10.24GlobeNewswireInventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

14.10.24GlobeNewswireInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

14.10.24GlobeNewswireInventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

25.09.24GlobeNewswireInventiva provides a corporate update and reports its unaudited 2024 first-half financial results

31.07.24GlobeNewswireInventiva Reports Preliminary 2024 First-Half Financial Information¹

25.07.24GlobeNewswireInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

19.07.24GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

18.07.24GlobeNewswireInventiva announces a €20.1 million issuance of royalty certificates

05.07.24GlobeNewswireInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

21.06.24GlobeNewswireDescription of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

21.06.24GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

30.05.24GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of May 13, 2024

Inventiva News

Inventiva News: auf dieser Seite finden Sie alle Inventiva News und Nachrichten zur Inventiva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Inventiva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Inventiva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.